Pavlov George 4

What Happened

• George Pavlov, a director of MapLight Therapeutics (MPLT), was granted equity awards on June 23, 2026: 3,932 restricted stock units (RSUs) and a 14,902-share stock option (both recorded at $0.00).
• These grants are director compensation — not open-market purchases or sales — so they reflect pay, not an independent buy/sell signal.

Key Details

• Transaction date: June 23, 2026; Form 4 filed June 25, 2026 (timely filing).
• Awards and amounts: 3,932 RSUs (each RSU = contingent right to one share) and a 14,902-share stock option (recorded as a derivative).
• Vesting: Both the RSUs and the option vest on the earlier of (i) June 23, 2027 or (ii) the issuer’s next annual stockholder meeting, subject to the reporting person’s continuous service.
• Source: Grants made under the Issuer’s 2025 Equity Incentive Plan and the company’s non-employee director compensation policy.
• Shares owned after transaction: not disclosed in the filing.

Context

• RSUs convert to actual shares only upon vesting; the option is a derivative that must vest (and typically be exercised) before shares are issued.
• These are routine director compensation awards and involve no cash paid by the director at grant. They do not, by themselves, indicate the director bought or sold stock.